Animal Modeling Services for Rare Lung Diseases
Protheragen is at the forefront of providing animal model development services for rare lung diseases to researchers worldwide. We understand the unique challenges of developing drugs and therapeutics for rare lung diseases and offer a full suite of customized services to help you accelerate your research and development process.
Challenges in In Vivo Studies of Rare Lung Diseases
In vivo studies of rare lung diseases face multiple challenges that stem from the nature of the rare diseases themselves as well as limitations in research resources.
Figure 1. Bleomycin induces inflammation, fibrosis, and epithelial remodeling. (Peng R, et al., 2013) We speculate on the challenges you may encounter in studying animal models of rare lung diseases:
- How do you accurately model the pathologic features and molecular mechanisms of rare lung diseases in humans?
- How to assess the effectiveness of therapeutic strategies, such as smoking cessation, medication, or surgical interventions?
- How to avoid stemming from other diseases (e.g., lung cancer) in animal models?
Our Services
We have extensive experience in the construction of animal models of rare lung diseases, including but not limited to the following models, which can highly mimic the characteristics of human diseases. We provide a full range of services from model construction, phenotyping to efficacy evaluation to meet your needs from early stage research to preclinical trials.
| Types of diseases | Types of animal models |
|---|---|
| Idiopathic pulmonary fibrosis | bleomycin-induced pulmonary fibrosis model GATA1-deficient mouse model Cdc42 knockout mouse model SiO2-induced pulmonary fibrosis model Radiation-induced pulmonary fibrosis model |
| Lymphangioleiomyomatosis | Xenograft tumor model Humanized xenograft tumor model Rat-derived xenograft tumor model |
| Pulmonary alveolar proteinosis | Animal models based on GM-CSF signaling disorders Animal model based on homeostatic imbalance of the alveolar internal environment Animal model based on exposure to hyperoxia |
| Pulmonary Langerhans cell histiocytosis | Genetically engineered mouse models that mimic abnormalities in the BRAF V600E mutation or other related molecular pathways |
| Pulmonary idiopathic hypertension | Model of wild lily base (MCT) induction Chronic hypoxia model Surgical shunt model Genetic modification models Sugen 5416+ hypoxia model Tobacco smoke exposure model |
| Cystic fibrosis | Cystic fibrosis mouse model Cystic fibrosis pig model Cystic fibrosis ferret model Cystic fibrosis rabbit model |
| Pulmonary amyloidosis | Transgenic mouse model Gelatin and starch filled material model |
Our Technique for Modeling Rare Lung Diseases
- Genetic Engineering and Gene Editing Technology
- Transgenic Technology
- Chemical Induction Technology
- Surgical and Physical Manipulation Technologies
- Cell Transplantation
Additional Services
After the animal model is established, we can assess the accuracy and reliability of the model through multi-omics analysis (e.g. genomics, transcriptomics, proteomics, etc.) and data analysis techniques.
Protheragen is a group of experienced scientists and technicians who provide you with professional technical support and consulting services. We uphold a rigorous scientific attitude to ensure that the experimental data is true and reliable, to help you quickly obtain high-quality research results. If you are interested in our services, please feel free to contact us for more details.
Reference
- Peng R, Sridhar S, Tyagi G, et al. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One. 2013;8(4):e59348.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.